Tag: Cancer: Prostate
Single-Dose Brachytherapy Effective for Prostate Cancer
Two-year and three-year biochemical progression-free survival rate of 100 percent for low-risk disease
Morbidity Low With Focal Laser Ablation of Prostate Cancer
Tumor diameter above the median was only significant predictor for positive MRI after treatment
AACR: Prostate Cancer Incidence Dropping, Stable in Most Countries
Decreases in mortality seen in 14 countries, stabilization in 54 of 71 countries
Docetaxel Chemo Ups Survival in High-Risk Localized Prostate Cancer
Findings based on addition of docetaxel chemotherapy to androgen suppression, radiotherapy
Testosterone Replacement Slows Prostate Cancer Recurrence
Being on testosterone replacement slows time to biochemical recurrence in multivariable analysis
Model Can Predict Survival in Nonmetastatic Prostate Cancer
Model demonstrated good discrimination for 15-year prostate cancer-specific mortality in validation cohorts
Stereotactic Body RT Promising for Low-, Intermediate-Risk PCa
Stereotactic body radiotherapy linked to low rates of severe toxic events, high rates of biochemical control
Low-Dose Aspirin Does Not Cut Death From Prostate Cancer
But during extended exposure periods of at least five years, low-dose aspirin may cut mortality
Darolutamide Slows Spread of Castration-Resistant Prostate Cancer
Significant survival benefit seen, adverse events similar between darolutamide and placebo
Use of Watchful Waiting Up for Low-Risk Localized Prostate Cancer
From 2010 to 2015, use of active surveillance/watchful waiting increased in low-risk disease
